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Abstract
Background: Depression is a leading cause of disability worldwide. To reduce the societal burden and improve quality
of life for individual patients, treatments for depression need to be optimized. There is a particular need for person-
tailored interventions that reinforce self-management of patients. Systematic self-monitoring and personalized feedback
through the Experience Sampling Method (ESM) could provide such a person-tailored, empowering intervention that
enhances treatment outcomes. The primary aim of this study is to investigate the efficacy of self-monitoring and
personalized feedback as an add-on tool in the treatment of depressive complaints in a natural setting.
Methods: The ZELF-i study is a pragmatic multi-site randomized controlled trial (RCT). We aim to recruit 150 individuals
with depressive symptoms aged between 18 and 65 years, who have an intake for outpatient basic or specialized
treatment at a mental health care organization in the North of the Netherlands. After the intake, participants will be
randomly allocated to one of three study arms: two experimental groups engaging in 28 days of systematic self-
monitoring (5 times per day) and receiving weekly personalized feedback on positive affect and activities (“Do”-module) or
on negative affect and thinking patterns (“Think”-module), and a control group receiving no additional intervention. Self-
report inventories of depressive symptoms, psychosocial functioning and feelings of empowerment will be administered
before and after the intervention period, and at follow-up measurements at 1, 2, 3 and 6 months. The patient-experienced
utility of the intervention will be investigated by a combination of quantitative and qualitative research methods.
Discussion: The present study is the first to examine the effects of add-on self-monitoring and personalized feedback on
depressive complaints in clinical practice. It is also the first to evaluate two different ESM modules targeted at both of
depression’s core symptoms. Lastly, it is the first study that uses a combination of qualitative and quantitative methods to
evaluate the patient-experienced utility of ESM with personalized feedback as an intervention for depression. Results of the
present study may improve treatment for depression, if the intervention is found to be effective.
Trial registration: Dutch Trial Register, NTR5707, registered prospectively 1 February 2016.
Keywords: Depression, Intervention, Self-monitoring, Personalized medicine, Experience sampling, Randomized Controlled
trial, E-health
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Background
According to the World Health Organization, the lead-
ing cause of disability worldwide is depression [1], a
common mental disorder that is characterized by two
core symptoms: depressed mood and decreased interest
or pleasure in activities [2]. Optimizing treatments for
depression will reduce the societal burden and improve
quality of life for individual patients. There is a particu-
lar need for cost-effective, personalized interventions
that support the mental health care sector and reinforce
self-management of patients (e.g., [3, 4]). Systematic
self-monitoring and personalized feedback on contextu-
alized patterns of affect through the Experience Sam-
pling Method (ESM) could provide such an
empowering, low-cost intervention.
With ESM, a patient gathers a multitude of prospective
in-the-moment daily life assessments on affect, behavior,
and context [5, 6]. Through aggregation of these systemat-
ically collected data, ESM can generate information that
goes beyond what has been explicitly listed by the patient.
Moreover, sophisticated analyses such as time-series ana-
lyses can determine the temporality of effects within a spe-
cific person, for instance, whether increased positive affect
(PA) precedes or follows an increase in physical activity.
ESM has generated important scientific insights in daily life
emotional dynamics in depressed patients (for reviews see
[7, 8]). Even more importantly, ESM also has great potential
for clinical practice and the individual patient, because it al-
lows personalized feedback (e.g., [9–11]. Small-scale
proof-of-principle studies have underlined the potential of
this approach for the individual patient (e.g., [10, 12, 13]).
Kauer and colleagues [14] investigated the efficacy of
self-monitoring and feedback on mood, stress, and daily ac-
tivities as a therapeutic tool for adolescents with emotional
or mental health issues in a larger study (n = 114). They
found that, compared to the control group (which only
monitored daily activities), emotional self-awareness in-
creased more in the intervention group, which in turn
decreased depressive symptoms. More recently, a pioneer
randomized controlled trial (RCT) established the efficacy
of ESM as a therapeutic tool for patients with depression
(n = 102, [15]). That is, add-on ESM-derived personalized
feedback on PA and activities resulted in a significantly and
clinically relevant stronger decrease in depressive symp-
toms compared to pharmacological treatment alone. While
promising, the ESM intervention was evaluated in the
absence of psychotherapy, which is a common part of de-
pression treatment, and had an extensive face-to-face
component itself. Therefore, it is not yet known whether
ESM as a self-management tool could have added positive
effects to treatments in regular clinical practice. In addition,
data acquisition as well as data analysis for the personalized
feedback reports were a laborious exercise, hampering use
in clinical practice.
We will take the necessary steps to move ESM-derived
personalized feedback closer towards implementation as a
therapeutic tool for depression in this study, which is named
the ZELF-i project to emphasize the self-management as-
pect of our approach (self = zelf in Dutch, i stands for inter-
vention). First, we will optimize the ESM intervention for
clinical practice by making it easily accessible on patients’
own smartphones and by reducing personnel investment
through automatized personalized analyses and digital feed-
back reports. Second, we will reexamine the previously re-
ported efficacy of ESM-derived personalized feedback on PA
and activities (ESM “Do-module”) in an RCT embedded in
a naturalistic clinical context. Third, we will examine the ef-
ficacy of an alternative ESM module focused on negative
affect (NA) and thinking patterns (ESM “Think-module”).
Until now, there have only been studies with one specific
module or a general set of items. Therefore, it is unknown
whether the form (systematic self-monitoring) or the con-
tent of an ESM module is relevant. Our two ESM modules
are both conceivably beneficial, as they link up with the two
main angles of psychotherapy for depression: behavioral ac-
tivation through positive reinforcement of activities, and
cognitive therapy aimed at helping individuals recognize and
replace negative thinking patterns [16].
Self-monitoring and personalized feedback through
ESM is a potential improvement for depressed patients for
several reasons. First, previous studies suggest clear health
benefits in terms of a decrease in depressive symptoms
[14, 15]. Second, in contrast to pharmacotherapy, the
intervention mobilizes patients as active agents in their
process to recovery, as evidenced by increases in feelings
of empowerment [17]. Third, the intervention supports
patients outside the clinician’s office, in their daily lives,
which is where changes should occur. Fourth,
person-tailored approaches should become the new focus
in mental health care according to national and inter-
national directives (e.g., [4]) and patient organizations
(e.g., Landelijk Platform GGZ). The intervention meets
this need by providing personalized feedback on relevant
aspects of daily life such as diurnal mood fluctuations,
affective reactivity to social and physical activities, and the
activation of negative thinking patterns in response to sad
mood. Fifth, patients can start directly after intake, making
the most out of the commonly long wait list period at
mental health organizations [18]. Considering that pa-
tients usually start seeking professional care out of a sense
of urgency, we hope that it will be satisfactory to them
that they will be able to start working on their problems
directly, without a period of passive waiting. Sixth, by
bringing their feedback reports in at the start of the treat-
ment, patients could commence specialized mental health
care programs with a kick-start. By already having moni-
tored their thoughts and feelings in relation to their activ-
ities for a couple of weeks, they are likely to have acquired
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a better insight in the processes involved in their depres-
sive symptoms and day-to-day functioning than patients
who did not partake in self-monitoring. Seventh, no costly
equipment is required, only a working smartphone, which
means the intervention could potentially reach many pa-
tients seeking care. In fact, interest among psychiatric out-
patients in using smartphones to monitor their mental
health is high [19].
According to guidelines for the development of
evidence-based directives, two independently performed
high-quality RCTs of substantive size provide the highest
level of proof for the efficacy of an intervention [20].
Thus, the proposed RCT could provide more definitive
answers regarding the efficacy of ESM as a therapeutic
tool for depression. While a reduction in depressive
symptomatology is important, we believe ‘health’ goes
beyond the traditional definition as the absence of ill-
ness. ESM-derived personalized feedback could assist pa-
tients in actively trying to gain more control over their
own psychological problems and enhance their function-
ing as evidenced by increases in feelings of empower-
ment [17] and increased engagement in social activities
[21]. These functional outcomes are at least as relevant
as clinical outcomes, as for many patients the essence of
recovery is to rise above the presumed limitations asso-
ciated with mental illness [22]. In fact, more and more
voices are calling for a reformulation of ‘health’ into the
ability to adapt and to self-manage in the face of social,
physical and emotional challenges (e.g., [23]). Therefore,
we will examine the impact of the ESM intervention not
only on depressive symptoms, but also on measures of
functioning and empowerment.
When evaluating an intervention not only the efficacy
on a group level is important, but the perspective of indi-
vidual patients also needs to be taken into account [24].
Qualitative methods in which the experiences and opin-
ions of patients are at the center, should be an essential
component of health care research [25]. Qualitative re-
search based on interviews with patients has shown that
an active attitude towards rehabilitation and structured at-
tention to oneself are important themes for individuals
with depression [26, 27]. ESM with personalized feedback
could meet these wishes, but there has been virtually no
research on patient experiences with such an intervention,
except for a personal case study by Peter Groot [10]. He
describes how self-monitoring of his mood helped him in
his recovery process as follows (p. 354): “I now look at my
own mood swings in a different way. I can accept more
easily the gloomy periods I still have once in a while; they
are briefer, I get through them more easily, and I think they
occur less frequently than in the past. I feel better ‘pro-
tected’ and more ‘empowered’ against the vulnerability with
which I have apparently been cursed.” It is not known
whether these experiences generalize to other individuals.
Therefore, a secondary aim of the ZELF-i project is to
evaluate the patient-experienced utility of ESM with per-
sonalized feedback through patient interviews.
Methods
ZELF-i is a multi-site trial designed according to the
principles of a pragmatic RCT to allow evaluation of the
intervention in real-life care facilities. Details are de-
scribed below according to the SPIRIT guidelines [28].
The study was approved by the Medical Ethical Commit-
tee of the University Medical Center Groningen (no.
2015/530). The trial has been registered prospectively in
the Dutch Trial Register (Nederlands Trial Register,
NTR5707, http://www.trialregister.nl) at 1 February
2016.
Participants
We will recruit 150 male and female adult patients re-
ferred for depressive complaints to general or specialized
outpatient teams at mental health care organizations in
the North of the Netherlands. Participants will be re-
cruited within the research network of mental health in-
stitutions in the North of The Netherlands, the Rob Giel
Research Center (https://www.rgoc.nl), which covers a
catchment area of over 4 million inhabitants. Eligibility
criteria are broad to include typical patients. Inclusion
criteria are: a) indication for depression treatment by the
mental health care professional (hereafter named: practi-
tioner); b) age between 18 and 65 years; and c) written
informed consent. Exclusion criteria are (based on prac-
titioners’ appraisals): a) crisis intervention warranted
(i.e., in the case of acute suicidality); b) presence of
psychotic or manic symptoms; and c) incapability of fol-
lowing research procedures due to inadequate Dutch
language proficiency, significant auditory or visual im-
pairments or mental retardation. Patients will be en-
rolled in regular treatment upon availability, that is, the
start of regular treatment will not be postponed until
participation in ZELF-i finishes. The ZELF-i intervention
is intended as an add-on tool at the start of care as usual
and thus circumstances are otherwise kept as ‘natural’ as
possible. Participants will receive travel reimbursements
and an additional €10 if they used the data bundle of
their own smartphone to participate in the intervention.
Procedure
Recruitment
An overview of the study design is presented in Fig. 1.
Individuals scheduled for intake at one of the participat-
ing mental health care teams will receive an information
letter about ZELF-i and a contact consent form together
with their intake invitation. Through the information let-
ter, participants will be made aware of the procedure
that, at the end of the intake, the practitioner will
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discuss the possibility to participate in ZELF-i with them
if a) depression treatment is indicated, and b) the practi-
tioner deems ZELF-i suited for the patient. Participants
will be made aware that participation is voluntary and
refusal to participate will not affect their treatment.
Patients decide independently whether they are interested
in the research and want to be contacted by the research
team by sending back the consent form or bringing it to
the intake at the mental health care institution. It is
important that eligible participants are enrolled in the study
shortly after the intake, because the intervention (28 days)
is designed to support participants early on and bridge po-
tential waiting periods between the intake and the start of
the indicated depression treatment in a constructive way.
Therefore, eligible participants will be contacted by a re-
search assistant preferably within a few days after the intake
to answer any questions and schedule an appointment for
the introduction session of the intervention study.
Introduction session and baseline measurement
The introduction session will take place at the mental
health care organization. At the start of the introduction
session, participants will have another opportunity to
ask questions about the study procedures. If everything
is clear, they will be asked to provide written informed
consent. After the informed consent procedure, partici-
pants will be randomly allocated to the control group or
one of two ESM intervention groups. Then, detailed in-
structions and practice runs for the ESM modules follow,
depending on the allocated treatment condition. Finally,
all participants will fill out questionnaires assessing
characteristics at baseline, depressive symptomatology,
functioning, empowerment, and questionnaires necessary
for cost-effectiveness analyses (see Study Parameters
section).
Randomization
Participants will be randomly allocated to the control group
or one of two ESM intervention groups (“Do-module” and
“Think-module”). Randomization (allocation ratio 1:1:1)
will be stratified per treatment location according to the
duration of antidepressant pharmacotherapy (new/switch
vs. maintenance, i.e., receiving antidepressant or mood sta-
bilizing medication for less vs. longer than 8 weeks prior to
study entry), and current psychotherapy (yes or no). For
these different strata, separate blocks with an allocation se-
quence of six with an equal condition distribution will be
created using an online randomization tool (https://
www.random.org/lists). Thus, each of the three conditions
will be present twice in a block of six. The allocation will be
implemented by using sequentially numbered sealed enve-
lopes (i.e., one pile of envelopes for each stratum). The allo-
cation will be done during the introduction session, by
team members who do not have access to the allocation se-
quence. Participants and research assistants are obviously
not blind to treatment. Practitioners are not blind to treat-
ment per se; participants decide themselves whether they
want to discuss their feedback reports with their (future)
therapist.
Intervention period
The ESM measurements consist of brief questionnaires
on the smartphone via a link to a secured website for
routine outcome monitoring (RoQua, https://www.ro-
qua.nl). Participants who do not have a smartphone of
their own will be provided with one for use during the
Fig. 1 Overview of the design of the randomized controlled trial. ESM = Experience Sampling Method. * The interview is optional and will take
place before the 2 month follow-up. ** The time interval between the start date of the participation in ZELF-i and the start date of regular
treatment varies between participants
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intervention period. Participants will be instructed how
to fill out the ESM measurements using their smart-
phone and how to interpret the questions. Participants
will fill out ESM measurements five times a day during
the course of their daily lives for 28 days. The measure-
ments will occur at set points in time during waking
hours (i.e., every three hours during the day, Fig. 2),
which will be programmed to optimally fit the partici-
pant’s usual daily rhythm.
Participants will be asked to complete their reports pref-
erably immediately after they receive a text message with
the link to the questionnaires. To minimize memory dis-
tortion, the link expires after 30 min. Participants will be
sent a reminder text message after 15 min if they did not
complete the measurement yet. During the ESM period,
the registration of the questionnaires is regularly checked
in RoQua. In case of > 10 subsequent missing measure-
ments, participants will receive a telephone call to ask
whether they want to stop the ESM measurements. Tech-
nical support will be available throughout the study.
For both ESM modules, each measurement starts with
questions about the participants’ current mood (PA, NA)
and physical state, followed by questions regarding activities
for the Do-module and hassles/uplifts and positive/negative
thoughts for the Think-module. In addition, the morning
measurements include a question about sleep, and the
evening measurements a few general questions on how par-
ticipants experienced the past day and how they feel about
the next day. The self-assessments will be rated on dichot-
omous scales (e.g., for the presence of hassles/uplifts) and
visual analogue scales (usually ranging from not at all (0) to
very much (100)). The items for the momentary question-
naires are presented in Additional file 1: Table S1.
Participants in the intervention groups receive personal-
ized feedback after each intervention week based on the
ESM measurements. This sums up to a total of 4 feedback
moments. After weeks 1–3, feedback will be e-mailed to
the participant in a digital report comprising text and sim-
ple graphs (e.g., pie charts, bar graphs). After week 4, a
final feedback report will be e-mailed, in which partici-
pants will also receive feedback on temporal relationships
between sets of variables (e.g., PA and physical activity
(Do-module), or NA and rumination (Think-module)). To
this end, time-series analysis will be employed on the
individual time series at the end of the ESM period.
Specifically, vector autoregression (VAR) models will be
applied, which are particularly suited for the investigation
of the temporal dynamics between two variables [29, 30].
For both ESM modules, the feedback reports will contain
increasingly rich information across the intervention period
by showing participants’ changes in affective responses in
daily life situations from week to week. This way, the partic-
ipants could become more aware of small improvements
and get increased control over influences on their mood. In
the Do-module, the feedback will also show changes in ac-
tivities since the start of the study and ultimately provide
information on the relationship between affective responses
in daily life and activities in order to refocus and redirect
the participants towards occasions for emotional strength.
In the Think-module, the feedback will not only show par-
ticipants’ changes in mood, but also negative and positive
thinking patterns across the intervention period. The final
report of the Think-module will provide information on the
relationship between affective responses in daily life and
thinking patterns such as rumination in order to make par-
ticipants aware of potential negative spirals.
A research assistant will discuss the final feedback report
with the participant during a debriefing session, which takes
place at the mental health care organization shortly after
the end of the intervention period. The research assistant
will answer questions and help participants provide mean-
ing to the graphs according to a standardized protocol. Per-
sonal notes will be made on the printed feedback report,
which the participant will take home. Feedback reports are
not sent to the (future) therapist by the researcher; partici-
pants can choose for themselves whether or not they want
to share this information. After discussing the feedback re-
port, participants fill out an evaluation questionnaire on the
ESM intervention and the regular questionnaires (control
participants fill out the latter at home). At a later point, the
intervention tool will also be evaluated through an add-
itional semi-structured interview in a subset of participants.
Participants are provided with an information letter about
this interview at the end of the debriefing session.
Follow up measurements
Consistent with a previous comparable RCT [15], partici-
pants will be invited (via e-mail) to fill-out questionnaires at
Fig. 2 Example of sampling times for the self-report assessments. The total sampling period covers 28 days
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1, 2, 3 and 6 months post-ESM (online via the RoQua sys-
tem). The participants will be able to fill out these forms at
home. In case of non-response, participants will receive an
e-mail and text message after 3 days to motivate them to fill
out the questionnaires. A complete overview of the (timing
of the) questionnaires is presented in Additional file 2:
Table S2 in the Study Parameters section.
Interview
To get a better view on whether ZELF-i has added value
to standard care, two psychologists will individually inter-
view a subset of participants in the two intervention
groups. The interviews will last for one hour and take
place at the mental health care organization. Not all par-
ticipants will be contacted for an interview; participants
will be selected at random until data saturation is
complete. Selected participants will be contacted by one
of two psychologists by telephone within 8 weeks after the
debriefing to answer questions and invite them to take
part in the interview. Participation in the interview is op-
tional, and independent of continued participation in the
follow-up measurements. At the interview appointment,
participants will be asked to sign a consent form specific
to the interview. The interview will be recorded with
audio equipment and processed into a transcript. The
anonymized transcripts will be coded independently by
two psychologist researchers, followed by a consensus dis-
cussion under supervision of a qualitative research expert.
After data coding, the audio recordings will be destroyed.
Data management
Data will be handled in a strictly confidential manner,
complying with the Dutch Personal Data Protection Act
(Wet Bescherming Persoonsgegevens). Each participant
will be assigned a unique identification number in order
to protect privacy. During data collection, team mem-
bers will have access to the contact details of the partici-
pants in order to contact them. After data collection,
only the principal investigator (JAB) of this study will
have access to the coding of the subjects. Other investi-
gators only have access to the coded files that do not
contain information that can be traced to a specific indi-
vidual. ESM and questionnaire data will be stored in
Medoq, a research environment within RoQua, which
cannot be accessed by practitioners. Participants choose
themselves whether they want to share their feedback re-
ports based on the ESM measurements with their practi-
tioners. Any non-digitalized questionnaire data will be
kept in locked cabinets in the investigator’s office.
As this intervention study does not include medical pro-
cedures we do not expect any serious adverse events to
occur. Any undesirable experience reported spontaneously
by the participants or observed by the investigator or her
staff during the study, whether or not considered related to
the experimental treatment, will be recorded as an adverse
event. For each participating centre, the principle investiga-
tor will notify the coordinating investigator of any adverse
and serious adverse events. A data monitoring committee
has not been installed as the added risk in comparison to
care as usual is negligible.
Study parameters
The main endpoints are based on questionnaires,
for which a complete overview is presented in
Additional file 2: Table S2.
Main study parameter
The primary outcome measure to determine efficacy of
the intervention will be the change in depression symp-
tom severity as measured by the self-report Inventory of
Depressive Symptomatology (IDS-SR, [31]) across 6 time
points: baseline, after 4 weeks of ESM and at 4 follow-up
measurements at 1, 2, 3, and 6 months (post-ESM). Partic-
ipants will be followed prospectively to compare the effi-
cacy of the intervention modules mutually and to the
control group.
The 30-item self-report Inventory of Depressive
Symptomatology (IDS-SR) includes all DSM-IV [2] diag-
nostic criterion items for major depressive disorder, as
well as commonly associated symptoms such as irritability
[31]. Each symptom item is scored on a scale from 0 to 3,
with higher scores denoting greater symptom severity.
The time frame for assessing symptom severity is the 7
day period prior to assessment (independent of whether
symptoms have been long-standing, chronic, or recent).
The IDS-SR is scored by summing the item responses. Ei-
ther appetite increase or decrease, and either weight in-
crease or decrease are used to calculate the score. If
increase and decrease items are both completed, the high-
est of the two scores is used. The IDS-SR has good psy-
chometric properties with high concurrent and internal
validity (Cronbach’s α = .92) and is sensitive to treatment
change [31, 32].
Secondary study parameters
From a patient perspective, functional outcomes are at
least as relevant as clinical outcomes. Therefore, we will
also assess change in psychosocial functioning by means
of the Outcome Questionnaire (OQ-45) [33]. In addition,
we will assess the extent to which individuals regain
self-esteem and take control over their own lives by means
of the Dutch Empowerment questionnaire (NEL) [34].
The Outcome Questionnaire-45 (OQ-45) is a 45-item
self-report scale that measures subjective discomfort, dis-
turbance in interpersonal relations, and functioning in so-
cial roles such as work and school [33]. Each item is
scored on a 5-point scale from never (0) to almost always
(4), yielding a range of possible scores of 0 to 180 with
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higher values indicating the endorsement of pathology.
The OQ-45 can be used on a weekly basis and extensive
validation in the United States has provided cut-off scores
for reliable change and recovery as markers for gauging
treatment success. Internal consistency (.90), test re-test re-
liability (.84 over 3 weeks in untreated participants), and
concurrent validity with other scales are high [35]. The
OQ-45 can be used regardless of the type of disorder or
type of therapy. The Dutch version of the OQ-45 showed
similar psychometric properties as the original instrument.
The Dutch Empowerment questionnaire (NEL) is a
40-item self-rating scale to assess patient empowerment,
developed by the Dutch Trimbos Institute in collabor-
ation with patients [34]. It incorporates six dimensions:
professional help, social support, own wisdom, sense of
belonging, self-management, and community inclusion.
Items are formulated in positive statements of strengths
as perceived by the individual and are rated on 5-point
scales ranging from 1 (‘strongly disagree’) to 5 (‘strongly
agree’), with the 4 items regarding professional health
care having the additional option ‘not applicable’. The
total score ranges from 40 to 200, with higher scores in-
dicating more empowerment. Previous research has
shown construct validity is satisfactory and internal
consistency (α = 0.93) is high [34]. The latter has been
corroborated by the ESM RCT in depression [17].
Other study parameters
To investigate whether ESM-derived feedback may be a
cost-effective strategy in participants with depression
from a societal perspective, we will administer question-
naires for costs due to illness and illness related costs
(TiC-P: Trimbos/iMTA questionnaire for Costs associ-
ated with Psychiatric Illness [36], adjusted for a mental
health population), and quality of life (Euroqol-5D) [37].
Similar questionnaires have also been used in the previous
RCT [15] to perform cost-effectiveness and cost-utility
analyses [17, 38]. In addition, we will extract information
on care use in the 2-year period after participation in
ZELF-i from the patient registries of the involved mental
health care organizations and from the regional psychi-
atric case registry (https://www.rgoc.nl/#home/onder-
zoek/Register), which will be linked to our sample when
approved by the participant (as stated on the informed
consent form).
To assess patient-experienced utility of the ESM mod-
ules, we will administer an evaluation questionnaire after
the ESM period. A small, randomly selected number of
participants (see sample size calculation) will be invited
to partake in a semi-structured interview with an experi-
enced practitioner. Central topics in this semi-structured
interview will include personal experiences with the
intervention in relation to depressive complaints (bur-
den, motivation), daily functioning, impact on daily
rhythm, self-management, and self-insight. In addition,
participants will be asked what improvements can be
made in the ESM modules and how the intervention
could be implemented in standard care. The interviews
will generate qualitative data.
At baseline, sociodemographic characteristics (gender,
age, educational level, work- and living situation), medica-
tion use, and current psychotherapy will be assessed by
means of a questionnaire. Two additional questionnaires
that will be administered are the Twenty-Item Toronto
Alexithymia Scale (TAS-20) [39, 40] and the revised ver-
sion of the Leiden Index of Depression Sensitivity
(LEIDS-R) [41, 42]. Alexithymia (literally: “no words for
emotions”) is a personality construct that is characterized
by difficulties in identifying and describing emotions.
Alexithymia is prevalent in approximately 10% of the gen-
eral population, and 32%–51% of participants with depres-
sive disorders [43, 44]. Since our intervention requires
participants to repeatedly rate themselves on various emo-
tional states, participants with high alexithymia scores
may find it more difficult to benefit from the intervention.
The LEIDS-R will be administered to assess cognitive
reactivity, that is the degree to which negative thinking
patterns are triggered by depressed mood. The interven-
tion requires participants to focus on their mood states,
and will possibly be less beneficial for participants who are
highly cognitively reactive, because an increased focus on
their mood may trigger negative thinking patterns.
Sample size calculation
The RCT comprises nomothetic (between-person) and
idiographic (within-person) aspects. The nomothetic as-
pect of the study is captured by questionnaire data (e.g.
self-reports on depressive symptoms), which will be used
for group-based analyses (e.g. tests of efficacy). The idio-
graphic aspect is captured by the ESM measurements,
which are used to provide participants with personalized
feedback. These two different types of quantitative ana-
lyses require different sample size calculations.
Group analyses
In the previous RCT, IDS-SR scores for the experimental
group (ESM + feedback) showed an initial 3-point drop
8 weeks after baseline, which increased to a 10-point
drop compared to baseline at 32 weeks [15]. With a
sample size of 40 per group, an alpha of 0.05 and an
intraclass correlation of 0.6 (between pre and post re-
peated measurements) we would have 85–99% power to
detect a 3–10 point difference in IDS-SR score between
each of our experimental groups compared to the con-
trol group [45]. In the previous RCT, about 10% of the
enrolled participants withdrew prematurely or only com-
pleted the ESM study partially [15]. Given that our study
has less face-to-face contact, commitment to the study
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protocol might be lower in our sample. To ensure we
will have 120 participants who completed the study ran-
domized over three conditions, we will enroll 150 partic-
ipants in the study (i.e., 50 per study arm).
Within-person analyses
Participants allocated to one of the two ESM modules will
record data using their smartphone five times a day for
28 days in their natural environment (N= 140 measure-
ments). This will provide ample data for the feedback re-
ports, which will mainly comprise descriptive statistics and
graphs (e.g., on daily fluctuations in mood and
week-by-week changes in average PA and NA). VAR model-
ing will be used to provide participants feedback on tem-
poral relationships between variables (e.g., PA and physical
activity). Exact sample size calculations are not possible in
studies using VAR, as it is typically unclear in such studies
what effect size can be expected. This is because analyses
are personalized and the direction of causality and the num-
ber of lagged influences in the system under investigation
are usually unknown [29]. However, previous work from
our and other groups suggests that a number of 60–90 mea-
surements is sufficient to reliably identify reciprocal associa-
tions between variables (e.g., [12, 13, 46]).
Qualitative analyses
Qualitative data will be collected through in-depth indi-
vidual interviews. The aim of the interviews is to provide
viewpoints on the added value of the ESM-modules
based on participants′ personal experiences. Data collec-
tion will be continued until no new themes emerge from
the data (data saturation procedure); for our confined re-
search question the estimated sample size is ~ 8–10 par-
ticipants per module [47].
Statistical analyses
Efficacy of the ESM-modules
The data have a hierarchical structure, because multiple
IDS-SR assessments will be clustered within participants.
Therefore, multilevel regression analyses will be used
with the two-way interaction between time (in weeks)
and treatment allocation as fixed effects, participants as
random intercept and a (linear or quadratic) random
slope for time (similar to [15]). This way, we can exam-
ine the effect of time on depressive symptoms (across 6
IDS-SR measurements), the effect of group (3 levels:
Do-module, Think-module, Control), and the interaction
between time and group separately. Similar analyses will be
performed to investigate the impact of the ESM-modules
on empowerment (NEL) and functioning (OQ-45). In order
to take into account individual differences regarding the
time interval between the start date of the participation in
ZELF-i and the start date of the treatment at the mental
health organization, a covariate “start date treatment – start
date ZELF-i” will be included in the analyses. Thresholds
for statistical significance will be set at p < .05.
Cost-effectiveness of the ESM-modules
Self-report instruments were completed assessing costs
(TIC-P), depressive symptoms (IDS-SR) and quality of
life (Euroqol-5D). First, a cost-effectiveness analysis will
be performed with the IDS-SR as primary outcome
measure. That is, cost effectiveness will be expressed in
terms of a ratio where the denominator is a gain in
health operationalized as a decrease in depressive symp-
tomatology and the numerator is the cost associated
with the health gain (i.e., direct (medical) costs and in-
direct (productivity losses) costs) assessed during the
ESM and follow-up period. The incremental
cost-effectiveness ratio will be determined on the basis
of incremental costs and effects of ZELF-i (Do-module
and Think-module) compared to usual care. Second, a
costs-utility analysis will be performed with quality
adjusted life years as the primary outcome measure
(based on the EuroQol-5D-3 L, a generic, self-report
instrument).
Patient-experienced utility of the ESM-modules
The patient-experienced utility of the ESM-modules will
be analysed in two ways: quantitatively in all participants
in the ESM arms through an evaluation questionnaire,
and qualitatively through in-depth semi-structured inter-
views in a subsample. Quantitative data will be presented
using descriptive statistics (mean, standard deviation).
Two sample t-tests (or a non-parametric variant) will be
used to examine differences between participants in the
Do-module and Think-module. Qualitative research pro-
duces textual data in the form of transcripts and observa-
tional field notes, which will be explored inductively using
content analysis to generate categories and explanations
[25]. For the interviews, a topic list has been created by
the researchers. After 4 interviews (2 Do-module, 2
Think-module), this topic list will be reviewed and newly
collected issues will be incorporated according to interim
analysis [25]. The adjusted topic list will be used for data
collection in the successive interviews [48]. This has the
advantage that the researchers can refine their questions
and stay open to new relevant themes and experiences,
which could be in contradiction to previously reported ex-
periences [25]. Data collection and data analysis will be
continued until no new themes emerge from the data (i.e.,
data saturation has been reached).
Missing data
Participants who drop-out during the intervention phase
will be asked to fill out the follow-up outcome question-
naires. Participants who complete less than 75% of the
ESM measurements during the intervention period, will
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receive descriptive feedback in their final report but not
feedback based on statistical models. Analyses will be
performed to examine whether the attrition rate relates
to participants’ demographic characteristics and levels of
depression. Missing data will be imputed by means of
multiple imputation.
Discussion
Recent studies have suggested that ESM may be an ef-
fective therapeutic tool for patients with depression [11],
which calls for further research in regular outpatient
care. The present pragmatic RCT will be the first to
examine the efficacy of self-monitoring and personalized
feedback as a stepping stone for the treatment of depres-
sive complaints in terms of added impact on depressive
symptomatology, empowerment and social functioning.
By starting directly after intake with ESM, we hope that
patients can make the most out of common wait list pe-
riods, and commence subsequent treatment programs
with a kick-start. ZELF-i is also the first study to evalu-
ate two different ESM intervention modules targeted at
both of depression’s core symptoms (ESM “Do-module”
and ESM “Think-module”), which will harbor knowledge
about what type of ESM-derived personalized feedback
is most effective. Lastly, it is the first study that uses a
combination of qualitative and quantitative methods to
evaluate the patient-experienced utility of ESM with per-
sonalized feedback as an intervention for depression.
Thus, the proposed study could provide more definitive
answers regarding the added value of ESM as a thera-
peutic tool for depression and potentially improve psy-
chiatric care for depression.
There are a couple of methodological issues that
should be considered beforehand. First, as participants
need to be motivated to fill out 5 measurements per day
for 28 days, the findings may not be generalizable to all
depressed patients. In a comparable ESM study, 39% of
the invited patients declined to participate [15]. That
said, generalizability issues play a role in virtually all
intervention studies, and this response rate is compar-
able to other RCTs in patients with depression (e.g.,
[49]). Once enrolled, 86% of the depressed participants
completed the 6-weeks intervention period in the
above-mentioned study [15], indicating that ESM was
feasible and acceptable for the majority of depressed pa-
tients. Second, the time between the ZELF-i intervention
and the start of the regular treatment will not be the
same across participants, because waiting list periods
vary across time and treatment locations. We will exam-
ine the impact of this variation in our analyses. Third,
there could be differences between the participating
mental health care institutions in the degree to which
ZELF-i is accepted by the practitioners and integrated in
care as usual. Therefore, we will explore potential
differences in the added value of ZELF-i between the dif-
ferent locations. Lastly, we cannot exclude there will be
a potential beneficial effect of the extra attention that
participants in the intervention groups receive compared
to the control group. However, we deemed a sham con-
dition in which participants fill out irrelevant question-
naires too demanding for patients. Furthermore, the
extra face-to-face contact is minimal compared to previ-
ous research [15]; participants in the intervention groups
only have one extra appointment with a research assist-
ant (debriefing) compared to the control group.
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